Provided by Tiger Trade Technology Pte. Ltd.

Defiance Daily Target 2X Long LLY ETF

22.08
+0.07000.32%
Post-market: 22.200.1200+0.54%19:11 EST
Volume:326.33K
Turnover:7.11M
Market Cap:41.62M
PE:- -
High:22.20
Open:21.60
Low:21.42
Close:22.01
52wk High:28.44
52wk Low:9.60
Shares:1.88M
Float Shares:1.71M
Volume Ratio:1.13
T/O Rate:19.14%
Dividend:0.70
Dividend Rate:3.19%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Texas sues Sanofi for allegedly 'bribing' providers to boost drug prescriptions

Reuters
·
1 hour ago

Insulet Corp. Stock Underperforms Thursday When Compared To Competitors

Dow Jones
·
2 hours ago

Eli Lilly initiated with an Overweight at Barclays

TIPRANKS
·
3 hours ago

Eli Lilly announces long-term data on Omvoh in Crohn’s disease

TIPRANKS
·
7 hours ago

Lilly Says Omvoh Maintains Steroid-Free Remission for Three Years in Crohn’s Disease Patients

Reuters
·
7 hours ago

Eli Lilly - Over 90% Maintained Steroid-Free Control Through Three Years

THOMSON REUTERS
·
7 hours ago

Eli Lilly Pushes Into Opioid Use Disorder With New Brenipatide Phase 2 Trial

TIPRANKS
·
8 hours ago

'She spent over $1,000 a month on weight-loss drugs': My son wrecked his finances after meeting his girlfriend. Who's to blame?

Dow Jones
·
Yesterday

Artiva Biotherapeutics Names Elaine Sorg to Board of Directors

Reuters
·
Yesterday

Berenberg Adjusts Price Target on Eli Lilly to $1,050 From $950, Maintains Hold Rating

MT Newswires Live
·
Yesterday

Three multinationals pay almost half of all Irish corporate tax, watchdog says

Reuters
·
Yesterday

U.S. RESEARCH ROUNDUP-EBay, Huntsman, Palo Alto

Reuters
·
Yesterday

Eli Lilly : Berenberg Raises Target Price to $1050 From $950

THOMSON REUTERS
·
Yesterday

Eli Lilly Stock (LLY) in Focus as Zepbound Found to Help Treat Psoriasis

TIPRANKS
·
Feb 18

Lurpak-maker Arla sees lower dairy prices and boost from protein products

Reuters
·
Feb 18

BRIEF-Lilly's Taltz (Ixekizumab) And Zepbound (Tirzepatide) Used Together Delivered Superior Efficacy In First-Of-Its-Kind Phase 3B Trial

Reuters
·
Feb 18

Lilly's Zepbound and Taltz improve psoriasis symptoms, drive weight loss in study

Reuters
·
Feb 18

Lilly's Taltz (Ixekizumab) and Zepbound (Tirzepatide) Used Together Delivered Superior Efficacy in First-of-Its-Kind Phase 3B Trial for Adults With Psoriasis and Obesity or Overweight

THOMSON REUTERS
·
Feb 18

Eli Lilly: Taltz, Zepbound Met Primary Endpoint of Superiority VS. Taltz Monotherapy in Achieving Complete Skin Clearance, ≥10% Weight Loss

THOMSON REUTERS
·
Feb 18

Eli Lilly: at 36 Weeks, Treatment With Taltz, Zepbound Met Primary and All Key Secondary Endpoints

THOMSON REUTERS
·
Feb 18